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Abstract
Background: The prognostic value of p53 protein expression in esophageal cancer has been evaluated, but the
results remain inconclusive and no consensus has yet been achieved. This meta-analysis was conducted to
quantitatively assess the prognostic significance of p53 expression in esophageal cancer.
Methods: Publications that assessed the clinical or prognostic significance of p53 expression in esophageal cancer
and were published before July 1, 2015 were identified by searching the PubMed and EMBASE databases.
A meta-analysis was performed to clarify the association between p53 expression and the clinical outcomes.
Results: A total of 36 publications met the criteria and included 4577 cases. Analysis of these data showed that
p53 expression in esophageal cancer was significantly associated with poorer 5-year survival (RR = 1.30, 95 % CI:
1.11–1.51, P = 0.0008). Subgroup analyses according to histological type, continent of the patients, and cut-off
value revealed the similar results. The results also indicated that p53 expression was highly associated with
advanced TNM stages (I/II vs. III/IV, OR = 0.74, 95 % CI: 0.55–0.99, P = 0.04), lymph node metastasis (OR = 0.77,
95 % CI: 0.66–0.90, P = 0.001), and distant metastasis (OR = 0.46, 95 % CI: 0.26–0.80, P = 0.006). However, p53
expression in the included studies was not significantly associated with tumor size (≤ 5 cm vs. > 5 cm, OR = 1.13, 95 %
CI: 0.92–1.40, P = 0.24), tumor location (upper + middle vs. lower, OR = 0.91, 95 % CI: 0.70–1.17, P = 0.45), grade
of differentiation (well + moderate vs. poor, OR = 1.10, 95 % CI: 0.90–1.34, P = 0.35), and the depth of invasion
(T1/T2 vs. T3/T4, OR = 0.86, 95 % CI: 0.71–1.03, P = 0.09).
Conclusions: This meta-analysis showed that p53 expression may be a useful biomarker for predicting poorer
prognosis in patients with esophageal cancer.
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Background
Esophageal cancer (EC), a highly aggressive and lethal
malignancy, causes 400 200 deaths worldwide and is the
sixth leading cause of cancer death in 2012 [1]. This ma-
lignancy includes two major histological types: esopha-
geal squamous cell carcinoma (ESCC) and esophageal
adenocarcinoma (EAC). Although the relevant diagnosis
and treatment methods have dramatically improved in
recent years, atypical early symptoms, middle-to-late
stage diagnosis, low treatment remission rates, and high
local recurrence rates continue to contribute to the poor
prognosis of patients with EC [2]. The increasing inci-
dence and poor prognosis of EC represent a major glo-
bal public health problem [3]. Despite advancements in
diagnostic and treatment methods in recent years, the
prognosis of patients with EC remains not ideal. Only a
small group of patients (15–30 %) survive five years after
surgery [4, 5]. Therefore, the detailed molecular mecha-
nisms involved in EC progression must be understood
and prognostic factors should be identified to enable the
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precise prediction of survival and selection of better
treatment and preventive measures for patients with EC.
A few biomarkers, including p53, vascular endothelial
growth factor (VEGF) [6], and CXC chemokine receptor
type 4 (CXCR4) [7], have recently emerged as prognostic
or predictive factors in EC. p53, a tumor-suppressor
gene, is located on the short arm of chromosome 17 and
displays the highest correlation with human types of
cancer uncovered thus far. This gene encodes the p53
protein, which acts as a transcription factor that plays a
key role in cell cycle regulation, DNA synthesis inhib-
ition, damaged DNA repair, and apoptosis [8, 9]. Under
normal conditions, p53 levels are low; in some cases,
they may even be undetectable [10]. However, the ex-
pression rate of p53 detected by immunohistochemistry
(IHC) has been reported to range from 33 to 70 % in
EC [11, 12]. p53 shows nuclear staining because of
accumulation of mutant p53, which often has an in-
creased stability and is resistant to degradation, making
it detectable by IHC [13]. A cell without mutation is
negative for IHC staining of p53 because no dye accu-
mulation occurs in the cell [14]. Although accumula-
tion of p53 detected by IHC does not necessarily imply
gene mutation, p53 over-expression in most of cases
(85 %) implies an underlying mutation [15]. Therefore,
p53 expression may be regarded as an indicator of p53
gene mutation.
Over the past decade, numerous studies have evalu-
ated the prognostic value of p53 protein expression in
EC. However, the results of these reports remain in-
conclusive and no consensus has yet been achieved.
Therefore, we conducted a systematic review and
meta-analysis to address the association between p53




We considered all studies on the association between
p53 and EC in this research. A systematic search was
performed with the following keywords or their combi-
nations: “p53” or “TP53” and “esophageal cancer” or
“esophageal carcinoma.” The search was performed in
the PubMed and EMBASE databases. The last search in
this study was updated in July 2015.
Inclusion criteria
All of the original studies must meet the following cri-
teria to be included in this meta-analysis: (1) Patients
were confirmed as EC by pathological examination. (2)
The expression of p53 in primary tumor tissues was de-
tected by IHC. (3) None of patients had received radi-
ation therapy or chemotherapy before surgery. (4) The
sample size was greater than 20. (5) The association
between p53 expression and overall survival (OS) of the
patients with EC was evaluated. (6) Sufficient data were
provided to allow the estimation of risk ratios (RRs) or
odds ratios (ORs) and their corresponding 95 % confi-
dence intervals (CI). (7) Only studies written in English
and Chinese were included in this study.
Exclusion criteria
The search was broadened by browsing the related sum-
mary, methods, and references of retrieved articles. The
title and abstract of each study identified in the search
were scanned to exclude clearly irrelevant publications.
The remaining articles were browsed to determine
whether they contained information on the topic of
interest. We excluded studies from this meta-analysis if
they were: (1) review articles, case reports, familiar stud-
ies, duplicated publications, conference abstracts, and
letters; (2) studies where p53 expression was evaluated
by a method other than IHC; (3) studies with sample
sizes less than 20; (4) studies without clinical data and
the relationship between p53 expression and disease
prognosis; (5) duplicate articles. For duplicate studies
based on identical or overlapping patient populations,
only the most recent and/or complete study was in-
cluded in this meta-analysis.
Data extraction
Information was carefully and independently extracted
from all eligible publications by two of the authors accord-
ing to the inclusion criteria listed above. Disagreement was
resolved by discussion between the two authors until a con-
sensus was reached. Data tables were constructed to extract
all relevant data from the text, tables, and figures of each
included study, including the author, publication year,
country of patient’s origin, tumor stage, number of patients,
research technique, and cut-off value of p53 expression.
When the prognosis was only plotted as a Kaplan–Meier
curve in some articles, Engauge Digitizer 4.1 software (from
https://sourceforge.net/projects/digitizer/) was applied to
digitize and extract the data.
Statistical analysis
ORs with 95 % CI were used to evaluate the association
between p53 expression and clinicopathological factors,
including the tumor TNM stage, tumor size, tumor loca-
tion, grade of differentiation, depth of invasion, lymph
node involvement, and distant metastasis. To stratify
data for analysis, the p53 expression and clinicopatho-
logical factors were combined into single categories with
comparable clinicopathological relevance: tumor TNM
staging (I/II vs. III/IV), lymph node (negative or posi-
tive), distant metastasis (negative or positive), tumor size
(≤ 5 cm vs. > 5 cm), tumor location (upper +middle vs.
lower), grade of differentiation (well + moderate vs.
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poor), and depth of invasion (T1/T2 vs. T3/T4). RRs
with 95 % CI were used to assess the association be-
tween p53 expression and the combined survival out-
come over several studies. The presence of heterogeneity
among studies was evaluated by the Dersimonian and
Laird’s Q test. I2 was used to quantify heterogeneity, and
an I2 value > 50 % was considered to represent substan-
tial heterogeneity between studies [16]. Compared with
fixed-effects models, random-effects models were found
to be more appropriate for the current study because of
the heterogeneity revealed by the forest plots. Hetero-
geneity often cannot be revealed by the Q test because
of its low power. The influence of individual studies on
the estimated summary effect was displayed in the sensi-
tivity analysis. In addition, funnel plots were used to esti-
mate the possible publication bias. Cochrane Review
Manager version 5.2 (Cochrane Library) was used to cal-




A total of 36 publications met the criteria for the ana-
lysis (Fig. 1). The total number of patients was 4577,
with 33–775 patients per study. The main characteristics
of the eligible studies, including the cut-off definition for
p53-positive results, are summarized in Table 1. All of the
studies determined the OS, and some reports included
clinicopathological factors. IHC was the only method used
to evaluate p53 expression in EC specimens.
Correlation of p53 expression with clinicopathological
parameters
The association between p53 and several clinicopatho-
logical parameters are illustrated in Fig. 2 and Table 2.
The p53 expression was highly correlated with more
advanced TNM stages (I/II vs. III/IV, OR = 0.74, 95 %
CI: 0.55–0.99, P = 0.04, Fig. 2a), lymph node metastasis
(OR = 0.77, 95 % CI: 0.66–0.90, P = 0.001, Fig. 2b), and
distant metastasis (OR = 0.46, 95 % CI: 0.26–0.80, P =
0.006, Fig. 2c). However, p53 expression was not signifi-
cantly associated with tumor size (≤ 5 cm vs. > 5 cm,
OR = 1.13, 95 % CI: 0.92–1.40, P = 0.24), tumor location
(upper + middle vs. lower, OR = 0.91, 95 % CI: 0.70–
1.17, P = 0.45), grade of differentiation (well + moderate
vs. poor, OR = 1.10, 95 % CI: 0.90–1.34, P = 0.35), and
depth of invasion (T1/T2 vs. T3/T4, OR = 0.86, 95 %
CI: 0.71–1.03, P = 0.09; Table 2).
Fig. 1 Literature search strategy and selection of articles
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p53 expression and five-year survival outcome
Based on the methods described above, the OS of 4577
patients in 36 studies were analyzed. The 5-year OS rate
was extracted from 32 studies. Meta-analysis of the 32
studies for the prognostic value of p53 expression
showed that increased expression was associated with
poorer OS. This trend was obtained from the M–H
random-effects model with a value of 1.30 (95 % CI:
1.11–1.51, P = 0.0008; Fig. 3), although heterogeneity be-
tween studies was noted (I2 = 66 %, Ph < 0.00001).
Subgroup analyses were conducted to address the het-
erogeneity observed in the correlation between p53
overexpression and decreased OS in EC patients, ac-
cording to histological type of EC, continent of the
Table 1 Characteristics of studies included in this meta-analysis
Study Country Type Source Cases p53 positive rate (%) IHC Cut off
(nuclear positivity)
Madani K, 2010 [12] Canada EAC esophagectomy 142 33.8 >10 %
Casson AG, 1998 [28] Canada ESCC/EAC esophagectomy 61 39 >10 %
Rosa AR, 2003 [29] Brazil ESCC esophagectomy 47 53.2 >10 %
Bahnassy AA, 2005 [30] Egypt ESCC/UC esophagectomy 50 68 >10 %
Egashira A, 2011 [31] Japan ESCC esophagectomy 94 56.4 >10 %
Chanvitan A, 1995 [32] Canada ESCC esophagectomy 80 50 >10 %
Murata, A, 2013 [33] Japan ESCC esophagectomy 266 52 weak-to-strong
Wang DY, 1994 [34] China ESCC esophagectomy 100 65 >30 %
Kato H, 2001 [35] Japan ESCC esophagectomy 89 55.1 >10 %
Flejou JF, 1994 [36] France EAC esophagectomy 62 66 ND
Shimaya K, 1993 [37] Japan ESCC esophagectomy 105 53 any nuclear positivity
Huang K, 2014 [38] China ESCC esophagectomy 118 49.2 >10 %
Lam KY, 1999 [39] China ESCC esophagectomy 153 64.1 >25 %
Chyczewski L, 1999 [40] Poland ESCC esophagectomy 33 45 >10 %
Cavazzola LT, 2009 [41] Brazil EAC esophagectomy 38 52.2 >10 %
Shang L, 2014 [42] China ESCC esophagectomy 590 43 >10 %
Yasuda M, 2000 [27] Japan EC esophagectomy 35 48.5 dark brown
Kuwahara M, 1999 [43] Japan EC esophagectomy 64 48.4 >10 %
Nita ME, 1999 [44] Brazil ESCC esophagectomy 62 50 >10 %
Ikeguchi M, 2000 [45] Japan ESCC esophagectomy 191 44.5 >50 %
Furihata M, 1993 [46] Japan ESCC esophagectomy 71 33.8 ND
Ahn MJ, 2002 [47] Korea ESCC/BSCC esophagectomy 81 51.9 >10 %
Hashimoto N, 1999 [48] Japan ESCC esophagectomy 73 64 >5 %
Makoto O, 2002 [49] Japan ESCC esophagectomy 96 46 >10 %
Hsu PK, 2008 [50] China ESCC esophagectomy 68 63.2 >25 %
Kanamoto A,1999 [51] Japan ESCC esophagectomy 239 48.1 >10 %
Hardwick RH, 1997 [52] UK ESCC/EAC esophagectomy 78 66.7 >10 %
Vijeyasingam R, 1994 [53] England ESCC/EAC esophagectomy 60 68.3 >5 %
Inada S, 1999 [54] Japan ESCC esophagectomy 40 52.5 >10 %
Nakamura T, 1995 [55] Japan ESCC esophagectomy 61 52 ND
Cheng TH, 2009 [56] China ESCC esophagectomy 119 51.3 >10 %
Yao W, 2014 [57] China ESCC esophagectomy or endoscopy 136 41.9 weak-to-strong
Takeno S, 2002 [58] Germany ESCC esophagectomy 71 36.6 >10 %
Xu XL, 2014 [59] China ESCC esophagectomy 775 35.9 >10 %
Takahashi Y, 2006 [60] Japan ESCC esophagectomy 180 61.7 >10 %
Goukon Y, 1994 [61] Japan ESCC esophagectomy 49 59 any nuclear positivity
UC undifferentiated carcinoma, BSCC basaloid squamous cell carcinoma, ND not documented
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patients, and cut-off value of IHC (Table 3). Results
showed the similar clinical significance of p53 expression
in each of the two major histological types (pure ESCC
cohorts: RR = 1.32, 95 % CI: 1.10–1.57, P = 0.002; pure
EAC cohorts: RR = 1.61, 95 % CI: 1.05–2.47, P = 0.03).
The association between p53 overexpression and poorer
OS in EC patients appeared to be greater among studies
involving patients from Europe and America (RR = 1.54,
95 % CI: 1.22–1.94, P = 0.0003) compared with studies
involving patients from Asia (RR = 1.24, 95 % CI: 1.04–
1.48, P = 0.02), and studies setting a none-10 % cut-off
value (RR = 1.56, 95 % CI: 1.35–1.81, P <0.00001)
Fig. 2 Forest plot of p53 expression and OR for clinicopathological features. The investigated clinicopathological parameters are TNM stage (a),
lymph node metastasis (b), and distant metastasis (c). ORs with the corresponding confidence intervals are shown
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compared with studies with a cut-off value of 10 % (RR =
1.18, 95 % CI: 0.96–1.45, P = 0.12).
Sensitivity analysis
To test for bias introduced by the low number of avail-
able eligible publications, we performed a sensitivity ana-
lysis. A single study in the meta-analysis was omitted
from each round of analysis to investigate the influence
of the individual data set of a particular study on the
pooled ORs. We found that the corresponding pooled
ORs were not essentially altered by the subtraction of
any study (data not shown), thereby indicating that our
results were statistically robust.
Publication bias
Funnel plots were performed to assess the publication
bias in this meta-analysis. The shape of the funnel plots
did not reveal obvious evidence of asymmetry (Fig. 4).
Discussion
The clinical significance and prognostic value of p53
expression in EC has recently been reported by several
investigators. In the present meta-analysis, we assess the
association between p53 expression and survival, as well
as the clinicopathological features in EC. A total of 36
relevant studies comprised of 4577 cases were subjected
to the final analysis.
Table 2 Meta-analysis of p53 expression and clinicopathological features of EC





I2 (%) P value
Tumor size (≤ 5 cm vs. > 5 cm) 4 1515 FEM 1.13 (0.92–1.40) 0.24 0 0.96
Tumor location (upper +middle vs. lower) 8 1205 FEM 0.91 (0.70–1.17) 0.45 0 0.80
Grade of differentiation (well + moderate vs. poor) 16 2328 FEM 1.10 (0.90–1.34) 0.35 17 0.26
Depth of invasion (T1/T2 vs. T3/T4) 13 2262 FEM 0.86 (0.71–10.3) 0.09 0 0.67
N number of studies, FEM fixed-effect model
Fig. 3 Analysis of p53 expression and survival of EC patients. Forest plot of RR for the OS included studies. Combined RR was calculated by a
random model
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The tumor suppressor gene p53 and its wild-type
protein play multiple functions in regulating cell cycle
progression, apoptosis, autophagy, differentiation, sen-
escence, and DNA repair functions, as well as influ-
ences cell metabolic pathways and cytokines [17].
However, if p53 is mutated, the mutant p53 protein
can accumulate in the cell nucleus [18], although in
some cases, nonsense mutations or a quickly degraded
mutant protein can cause lack of expression [13].
Therefore, p53 over-expression is generally associated
with the inactivation of p53 [19]. Based on its func-
tions, positive p53 expression in cancer cells may
Table 3 Subgroup meta-analyses of p53 expression and survival according to histological type, continent and cut-off value





I2 (%) P value
Histological type
ESCC only 23 3454 1.32 (1.10–1.57) 0.002 REM 70 < 0.00001
EAC only 3 242 1.61 (1.05–2.47) 0.03 FEM 16 0.3
Continent
Asia 22 3372 1.24 (1.04–1.48) 0.02 REM 72 < 0.00001
Europe and America 9 640 1.54 (1.22–1.94) 0.0003 FEM 30 0.18
Cut-off value
10 % 20 2949 1.18 (0.96–1.45) 0.12 REM 71 < 0.00001
None-10 % 12 1113 1.56 (1.35–1.81) < 0.00001 FEM 44 0.05
N number of studies, FEM fixed-effect model, REM random-effect model
Fig. 4 Publication bias determination using funnel plot. Funnel plots of TNM stage (a), lymph node metastasis (b), distant metastasis (c), and
5-year survival (d)
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promote cell migration, invasion, and metastasis, fi-
nally leading to poor prognosis [20]. In human can-
cers, the p53 gene is the most commonly mutated
gene; positive expression of p53 has been correlated
with the clinicopathological features and prognosis of
breast cancer [21], bladder cancer [22], and other
types of cancer.
The results of the overall pooled analysis in the
present study on the association of p53 expression with
survival in EC patients suggested that positive p53 ex-
pression was significantly related to poorer OS (RR =
1.30, 95 % CI: 1.11–1.51). These findings demonstrated
the significance of p53 expression in the prognosis of pa-
tients with EC and agreed with the theoretical inference
that patients with positive p53 expression, which is often
cause by mutation, could have poorer clinical prognosis
than those with negative p53 expression. The same re-
sults have been reported in the meta-analyses of gastric
cancer [23], osteosarcoma [24], hepatocellular carcinoma
[25], and other tumors.
We also analyzed the relationship between p53 and
clinicopathological parameters; the results showed that
p53 expression was significantly associated with more
advanced TNM stages (I/II vs. III/IV, OR = 0.74, 95 %
CI: 0.55–0.99), lymph node metastasis (OR = 0.77, 95 %
CI: 0.66–0.90), and distant metastasis (OR = 0.46, 95 %
CI: 0.26–0.80). Given that a more advanced TNM stage,
positive lymph node metastasis, and distant metastasis
are adverse prognostic features, the present results may
explain why positive p53 expression is associated with
poor 5-year survival in patients with EC. However, no
significant associations were observed between p53 ex-
pression and tumor size, tumor location, grade of differ-
entiation, and depth of invasion in this study.
The current study presented several limitations that
should be considered. First, the heterogeneity across
studies was high for some parameters of this disease.
Therefore, even if the random-effects models are used to
take heterogeneity into account and several heterogen-
eity analyses were performed, some estimates should be
interpreted with caution. The second limitation involves
the lacking of a defined standardized protocol and evalu-
ation system to measure p53 expression by IHC in vari-
ous studies; several factors, such as differences in types
of antibodies, concentrations, and cut-off values used
may lead to potential bias. Nevertheless, the sensitivity
of IHC to assess p53 mutations through protein accu-
mulation is generally poor; some mutations, such as
truncated mutant, can lead to complete loss of p53
staining and be missed by IHC [13, 26, 27]. Combining
IHC and other widely applicable techniques, which
could detect p53 gene aberrations, would potentially im-
prove the accuracy of p53 as a clinical biomarker for
predicting EC progression. Third, the full text of studies
in this meta-analysis were published only in English or
Chinese. Non-significant or negative findings are usually
not published and other potential eligible studies may
have been excluded; these factors also contribute to bias.
We included the data of 4577 patients in this meta-
analysis to provide a foundation for a larger prospective
study.
Conclusions
In conclusion, our findings indicate that positive p53 ex-
pression is independently and significantly associated
with poorer 5-year survival, more advanced TNM stages,
lymph node metastasis, and distant metastasis in pa-
tients with EC. The expression of p53 may be a useful
biomarker to predict a poorer prognosis for EC patients.
However, to strengthen our findings, larger prospective
studies with better standardized methods are needed to
provide a comprehensive conclusion regarding the prog-
nostic role of p53 expression in EC.
Abbreviations
BSCC, basaloid squamous cell carcinoma; CI, confidence interval; EAC,
esophageal adenocarcinoma; EC, esophageal cancer; ESCC, esophageal
squamous cell carcinoma; FEM, fixed-effect model; IHC, immunohistochemistry;
N, number of studies; ND, not documented; OR, odds ratio; OS, overall survival;




This work was supported by grants from the National Natural Science
Foundation of China (No.81460416, 81560399), the Ministry of Science and
Technology of China (2012AA02A503), and the Scientific Research Start-up
Capital for High-level Talents of Shihezi University (RCZX201444,
RCZX201229).
Availability of data and materials
The datasets supporting the conclusions of this article are included within
the article.
Authors’ contributions
LW, JH and FL conceived the study. XY and ZZ searched the databases and
extracted the data. LW, XY, JL and JH assembled and analyzed the data.
LW and LJ gave advice on meta-analysis methodology. XY wrote the draft
of the paper. LW, JH and LF revised the manuscript. All authors have read
and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Not applicable.
Author details
1Department of Pathology and Key Laboratories for Xinjiang Endemic and
Ethnic Diseases, Shihezi University School of Medicine, Shihezi, Xinjiang,
China. 2Department of Immunology, Shihezi University School of Medicine,
Shihezi, Xinjiang, China. 3Department of Pathology, Beijing Chaoyang
Hospital, Capital Medical University, Beijing, China.
Wang et al. BMC Cancer  (2016) 16:373 Page 8 of 10
Received: 28 January 2016 Accepted: 27 June 2016
References
1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer
statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.
2. Chen J, Wu F, Pei HL, Gu WD, Ning ZH, Shao YJ, Huang J. Analysis of the
correlation between P53 and Cox-2 expression and prognosis in esophageal
cancer. Oncol Lett. 2015;10(4):2197–203.
3. Belkhiri A, El-Rifai W. Advances in targeted therapies and new promising
targets in esophageal cancer. Oncotarget. 2015;6(3):1348–58.
4. Jemal A, Simard EP, Dorell C, Noone AM, Markowitz LE, Kohler B, Eheman C,
Saraiya M, Bandi P, Saslow D, et al. Annual Report to the Nation on the Status of
Cancer, 1975–2009, featuring the burden and trends in human
papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels. J
Natl Cancer Inst. 2013;105(3):175–201.
5. Morita M, Yoshida R, Ikeda K, Egashira A, Oki E, Sadanaga N, Kakeji Y, Yamanaka T,
Maehara Y. Advances in esophageal cancer surgery in Japan: an analysis of 1000
consecutive patients treated at a single institute. Surgery. 2008;143(4):499–508.
6. Peng J, Shao N, Peng H, Chen LQ. Prognostic significance of vascular
endothelial growth factor expression in esophageal carcinoma: a meta-
analysis. J BUON. 2013;18(2):398–406.
7. Wu J, Wu X, Liang W, Chen C, Zheng L, An H. Clinicopathological and prognostic
significance of chemokine receptor CXCR4 overexpression in patients with
esophageal cancer: a meta-analysis. Tumour Biol. 2014;35(4):3709–15.
8. Soussi T. The p53 pathway and human cancer. Br J Surg. 2005;92(11):1331–2.
9. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation
of p53 protein in the cellular response to DNA damage. Cancer Res. 1991;
51(23 Pt 1):6304–11.
10. Wang X, Simpson ER, Brown KA. p53: protection against tumor growth
beyond effects on cell cycle and apoptosis. Cancer Res. 2015;75(23):5001–7.
11. Patel DD, Bhatavdekar JM, Chikhlikar PR, Patel YV, Shah NG, Ghosh N, Suthar TP,
Balar DB. Clinical significance of p53, nm23, and bcl-2 in T3-4N1M0 oesophageal
carcinoma: an immunohistochemical approach. J Surg Oncol. 1997;65(2):111–6.
12. Madani K, Zhao R, Lim HJ, Casson AG. Prognostic value of p53 mutations in
oesophageal adenocarcinoma: final results of a 15-year prospective study.
Eur J Cardiothorac Surg. 2010;37(6):1427–32.
13. Davelaar AL, Calpe S, Lau L, Timmer MR, Visser M, Ten Kate FJ, Parikh KB,
Meijer SL, Bergman JJ, Fockens P, et al. Aberrant TP53 detected by
combining immunohistochemistry and DNA-FISH improves Barrett’s
esophagus progression prediction: a prospective follow-up study. Genes
Chromosomes Cancer. 2015;54(2):82–90.
14. Pietrantonio F, De Braud F, Da Prat V, Perrone F, Pierotti MA, Gariboldi M, Fanetti G,
Biondani P, Pellegrinelli A, Bossi I, et al. A review on biomarkers for prediction of
treatment outcome in gastric cancer. Anticancer Res. 2013;33(4):1257–66.
15. Baas IO, Mulder JW, Offerhaus GJ, Vogelstein B, Hamilton SR. An evaluation
of six antibodies for immunohistochemistry of mutant p53 gene product in
archival colorectal neoplasms. J Pathol. 1994;172(1):5–12.
16. Lin J, Albers AE, Qin J, Kaufmann AM. Prognostic significance of
overexpressed p16INK4a in patients with cervical cancer: a meta-analysis.
PLoS One. 2014;9(9):e106384.
17. Levine AJ, Oren M. The first 30 years of p53: growing ever more complex.
Nat Rev Cancer. 2009;9(10):749–58.
18. Dowell SP, Wilson PO, Derias NW, Lane DP, Hall PA. Clinical utility of the
immunocytochemical detection of p53 protein in cytological specimens.
Cancer Res. 1994;54(11):2914–8.
19. Cordon-Cardo C, Dalbagni G, Saez GT, Oliva MR, Zhang ZF, Rosai J, Reuter VE,
Pellicer A. p53 mutations in human bladder cancer: genotypic versus phenotypic
patterns. Int J Cancer. 1994;56(3):347–53.
20. Muller PA, Vousden KH, Norman JC. p53 and its mutants in tumor cell
migration and invasion. J Cell Biol. 2011;192(2):209–18.
21. Bourdon JC, Khoury MP, Diot A, Baker L, Fernandes K, Aoubala M, Quinlan P,
Purdie CA, Jordan LB, Prats AC, et al. p53 mutant breast cancer patients
expressing p53gamma have as good a prognosis as wild-type p53 breast
cancer patients. Breast Cancer Res. 2011;13(1):R7.
22. Zhou X, Zhang G, Tian Y. p53 Status correlates with the risk of recurrence in
non-muscle invasive bladder cancers treated with Bacillus Calmette-Guerin:
a meta-analysis. PLoS One. 2015;10(3):e0119476.
23. Wei K, Jiang L, Wei Y, Wang Y, Qian X, Dai Q, Guan Q. The prognostic
significance of p53 expression in gastric cancer: a meta-analysis. J Cancer
Res Clin Oncol. 2015;141(4):735–48.
24. Yao D, Cai GH, Chen J, Ling R, Wu SX, Li YP. Prognostic value of p53
alterations in human osteosarcoma: a meta analysis. Int J Clin Exp Pathol.
2014;7(10):6725–33.
25. Liu J, Ma Q, Zhang M, Wang X, Zhang D, Li W, Wang F, Wu E. Alterations of
TP53 are associated with a poor outcome for patients with hepatocellular
carcinoma: evidence from a systematic review and meta-analysis. Eur J
Cancer (Oxford, England : 1990). 2012;48(15):2328–38.
26. Fichter CD, Herz C, Munch C, Opitz OG, Werner M, Lassmann S. Occurrence of
multipolar mitoses and association with Aurora-A/-B kinases and p53
mutations in aneuploid esophageal carcinoma cells. BMC Cell Biol. 2011;12:13.
27. Yasuda M, Kuwano H, Watanabe M, Toh Y, Ohno S, Sugimachi K. p53
expression in squamous dysplasia associated with carcinoma of the
oesophagus: evidence for field carcinogenesis. Br J Cancer. 2000;83(8):1033–8.
28. Casson AG, Tammemagi M, Eskandarian S, Redston M, McLaughlin J, Ozcelik H.
p53 alterations in oesophageal cancer: association with clinicopathological
features, risk factors, and survival. Mol Pathol. 1998;51(2):71–9.
29. Rosa AR, Schirmer CC, Gurski RR, Meurer L, Edelweiss MI, Kruel CD. Prognostic
value of p53 protein expression and vascular endothelial growth factor
expression in resected squamous cell carcinoma of the esophagus. Dis
Esophagus. 2003;16(2):112–8.
30. Bahnassy AA, Zekri ARN, Abdallah S, El-Shehaby AMR, Sherif GM. Human
papillomavirus infection in Egyptian esophageal carcinoma: correlation with p53,
p21waf, mdm2, C-erbB2 and impact on survival. Pathol Int. 2005;55(2):53–62.
31. Egashira A, Morita M, Yoshida R, Saeki H, Oki E, Sadanaga N, Kakeji Y, Tsujitani S,
Maehara Y. Loss of p53 in esophageal squamous cell carcinoma and the
correlation with survival: analyses of gene mutations, protein expression, and loss
of heterozygosity in Japanese patients. J Surg Oncol. 2011;104(2):169–75.
32. Chanvitan A, Nekarda H, Casson AG. Prognostic value of DNA index, S-phase
fraction and p53 protein accumulation after surgical resection of esophageal
squamous-cell carcinomas in Thailand. Int J Cancer. 1995;63(3):381–6.
33. Murata A, Baba Y, Watanabe M, Shigaki H, Miyake K, Karashima R, Imamura Y, Ida S,
Ishimoto T, Iwagami S, et al. P53 immunohistochemical expression and patient
prognosis in esophageal squamous cell carcinoma. Med Oncol. 2013;30(4):728.
34. Wang DY, Xiang YY, Tanaka M, Li XR, Li JL, Shen Q, Sugimura H, Kino I. High
prevalence of p53 protein overexpression in patients with esophageal cancer in
Linxian, China and its relationship to progression and prognosis. Cancer. 1994;
74(12):3089–96.
35. Kato H, Yoshikawa M, Miyazaki T, Nakajima M, Fukai Y, Tajima K, Masuda N,
Tsukada K, Fukuda T, Nakajima T, et al. Expression of p53 protein related to
smoking and alcoholic beverage drinking habits in patients with esophageal
cancers. Cancer Lett. 2001;167(1):65–72.
36. Flejou JF, Paraf F, Potet F, Muzeau F, Fekete F, Henin D. p53 protein
expression in Barrett’s adenocarcinoma: a frequent event with no
prognostic significance. Histopathology. 1994;24(5):487–9.
37. Shimaya K, Shiozaki H, Inoue M, Tahara H, Monden T, Shimano T, Mori T.
Significance of p53 expression as a prognostic factor in oesophageal squamous
cell carcinoma. Virchows Arch A Pathol Anat Histopathol. 1993;422(4):271–6.
38. Huang K, Chen L, Zhang J, Wu Z, Lan L, Wang L, Lu B, Liu Y. Elevated p53
expression levels correlate with tumor progression and poor prognosis in
patients exhibiting esophageal squamous cell carcinoma. Oncol Lett. 2014;
8(4):1441–6.
39. Lam KY, Law S, Tin L, Tung PH, Wong J. The clinicopathological significance
of p21 and p53 expression in esophageal squamous cell carcinoma: an
analysis of 153 patients. Am J Gastroenterol. 1999;94(8):2060–8.
40. Chyczewski L, Kozlowski M, Niklinski J, Szyszko J, Laudanski J, Niklinska W.
p53 protein expression in resected invasive esophageal cancer. Neoplasma.
1999;46(3):150–5.
41. Cavazzola LT, Rosa AR, Schirmer CC, Gurski RR, Telles JP, Mielke F, Meurer L,
Edelweiss MI, Kruel CD. Immunohistochemical evaluation for P53 and VEGF
(Vascular Endothelial Growth Factor) is not prognostic for long term survival in
end stage esophageal adenocarcinoma. Rev Col Bras Cir. 2009;36(1):24–34.
42. Shang L, Liu HJ, Hao JJ, Jiang YY, Shi F, Zhang Y, Cai Y, Xu X, Jia XM, Zhan
QM, et al. A panel of overexpressed proteins for prognosis in esophageal
squamous cell carcinoma. PLoS One. 2014;9(10):e111045.
43. Kuwahara M, Hirai T, Yoshida K, Yamashita Y, Hihara J, Inoue H, Toge T. p53,
p21(Waf1/Cip1) and cyclin D1 protein expression and prognosis in
esophageal cancer. Dis Esophagus. 1999;12(2):116–9.
44. Nita ME, Nagawa H, Tominaga O, Tsuno N, Hatano K, Kitayama J, Tsuruo T,
Domene CE, Muto T. p21Waf1/Cip1 expression is a prognostic marker in
curatively resected esophageal squamous cell carcinoma, but not p27Kip1,
p53, or Rb. Ann Surg Oncol. 1999;6(5):481–8.
Wang et al. BMC Cancer  (2016) 16:373 Page 9 of 10
45. Ikeguchi M, Oka S, Gomyo Y, Tsujitani S, Maeta M, Kaibara N. Combined
analysis of p53 and retinoblastoma protein expressions in esophageal
cancer. Ann Thorac Surg. 2000;70(3):913–7.
46. Furihata M, Ohtsuki Y, Ogoshi S, Takahashi A, Tamiya T, Ogata T. Prognostic
significance of human papillomavirus genomes (type-16, -18) and aberrant
expression of p53 protein in human esophageal cancer. Int J Cancer. 1993;
54(2):226–30.
47. Ahn MJ, Jang SJ, Park YW, Choi JH, Oh HS, Lee CB, Paik HK, Park CK. Clinical
prognostic values of vascular endothelial growth factor, microvessel density,
and p53 expression in esophageal carcinomas. J Korean Med Sci. 2002;17(2):
201–7.
48. Hashimoto N, Tachibana M, Dhar DK, Yoshimura H, Nagasue N. Expression
of p53 and RB proteins in squamous cell carcinoma of the esophagus: their
relationship with clinicopathologic characteristics. Ann Surg Oncol. 1999;
6(5):489–94.
49. Makoto O, Takeda A, Ting-Leig L, Shinnichi O, Hisahiro M, Yutaka F,
Yoshihiro N, Kobayashi S, Gunji Y, Suzuki T, et al. Prognostic significance of
thymidine phosphorylase and p53 co-expression in esophageal squamous
cell carcinoma. Oncol Rep. 2002;9(1):23–8.
50. Hsu PK, Li AF, Wang YC, Hsieh CC, Huang MH, Hsu WH, Hsu HS. Reduced
membranous beta-catenin protein expression is associated with metastasis
and poor prognosis in squamous cell carcinoma of the esophagus. J Thorac
Cardiovasc Surg. 2008;135(5):1029–35.
51. Kanamoto A, Kato H, Tachimori Y, Watanabe H, Nakanishi Y, Kondo H,
Yamaguchi H, Gotoda T, Muro K, Matsumura Y. No prognostic significance
of p53 expression in esophageal squamous cell carcinoma. J Surg Oncol.
1999;72(2):94–8.
52. Hardwick RH, Barham CP, Ozua P, Newcomb PV, Savage P, Powell R,
Rahamin J, Alderson D. Immunohistochemical detection of p53 and c-erbB-
2 in oesophageal carcinoma; no correlation with prognosis. Eur J Surg
Oncol. 1997;23(1):30–5.
53. Vijeyasingam R, Darnton SJ, Jenner K, Allen CA, Billingham C, Matthews HR.
Expression of p53 protein in oesophageal carcinoma: clinicopathological
correlation and prognostic significance. Br J Surg. 1994;81(11):1623–6.
54. Inada S, Koto T, Futami K, Arima S, Iwashita A. Evaluation of malignancy and
the prognosis of esophageal cancer based on an immunohistochemical
study (p53, E-cadherin, epidermal growth factor receptor). Surg Today. 1999;
29(6):493–503.
55. Nakamura T, Ide H, Eguchi R, Hayashi K, Hanyu F, Nagasako K, Yukawa M,
Asaka K, Fujimori T, Maeda S. Expression of p53 protein related to human
papillomavirus and DNA ploidy in superficial esophageal carcinoma. Surg
Today. 1995;25(7):591–7.
56. Cheng TH, Hsu PK, Li AF, Hung IC, Huang MH, Hsu HS. Correlation of p53,
MDM2 and p14(ARF) protein expression in human esophageal squamous
cell carcinoma. J Cancer Res Clin Oncol. 2009;135(11):1577–82.
57. Yao W, Qin X, Qi B, Lu J, Guo L, Liu F, Liu S, Zhao B. Association of p53
expression with prognosis in patients with esophageal squamous cell
carcinoma. Int J Clin Exp Pathol. 2014;7(10):7158–63.
58. Takeno S, Noguchi T, Kikuchi R, Uchida Y, Yokoyama S, Muller W. Prognostic
value of cyclin B1 in patients with esophageal squamous cell carcinoma.
Cancer. 2002;94(11):2874–81.
59. Xu XL, Zheng WH, Tao KY, Li XX, Xu WZ, Wang Y, Zhu SM, Mao WM. p53 is
an independent prognostic factor in operable esophageal squamous cell
carcinoma: a large-scale study with a long follow-up. Med Oncol. 2014;
31(11):1–7.
60. Takahashi Y, Noguchi T, Takeno S, Kimura Y, Okubo M, Kawahara K. Reduced
expression of p63 has prognostic implications for patients with esophageal
squamous cell carcinoma. Oncol Rep. 2006;15(2):323–8.
61. Goukon Y, Sasano H, Nishihira T, Nagura H, Mori S. p53 overexpression in
human esophageal carcinoma: A correlation with tumor DNA ploidy and
two parameter flow cytometric study. Anticancer Res. 1994;14(3 B):1305–12. •  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Wang et al. BMC Cancer  (2016) 16:373 Page 10 of 10
